Welcome to our dedicated page for Acadia Pharmaceuticals SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acadia Pharmaceuticals Inc. filings document the regulatory record for a commercial biopharmaceutical company focused on neurological and rare diseases. Recent Form 8-K reports furnish quarterly and annual operating results, product-sales disclosures for NUPLAZID and DAYBUE, corporate presentations and Regulation FD materials, and updates tied to research-and-development leadership.
Proxy and governance filings describe board composition, committee service, director compensation, executive compensation, equity-incentive awards and annual meeting matters. The filings also record board appointments and resignations, non-employee director compensation under equity plans, and other material-event disclosures affecting Acadia’s governance and capital structure.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
ACADIA PHARMACEUTICALS INC reported equity compensation grants linked to Baker-related entities and funds. The filing shows awards connected to board service by Julian C. Baker and Dr. Stephen R. Biggar, where the Baker funds have an indirect pecuniary interest.
The grants include a total of 18,622 restricted stock units and 32,008 non-qualified stock options, reported for the funds because each fund has an indirect pecuniary interest in these securities. The stock options carry a strike price of $21.66, vest in four equal quarterly installments beginning on May 29, 2026, and expire on May 28, 2036. The adviser has voting and dispositive power over the options, RSUs, and any common stock issued from them, while Julian C. Baker, Felix J. Baker, Baker Bros. Advisors LP, and its general partner disclaim beneficial ownership except to the extent of their pecuniary interest.
ACADIA Pharmaceuticals director Edmund Harrigan reported compensation-related equity activity, not open-market trading. On May 29, 2026, he exercised restricted stock units into 8,107 shares of common stock, bringing his direct common stock holdings to 43,148 shares.
He also received new awards on the same date: 9,311 restricted stock units, each representing a right to one share of common stock, and 16,004 director stock options with a $21.66 exercise price expiring on May 28, 2036. The new RSUs and options vest over roughly one year or until the next annual stockholders’ meeting, aligning his compensation with shareholder outcomes.
ACADIA PHARMACEUTICALS INC director Adora Ndu reported equity compensation activity and an option exercise. On May 29, 2026, Ndu exercised restricted stock units covering 8,107 shares of common stock, bringing direct common stock holdings to 32,908 shares.
Ndu also received 9,311 new restricted stock units and 16,004 director stock options with an exercise price of $21.66 per share. According to the footnotes, the 9,311 restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting, while the options vest quarterly over one year on a similar schedule. The filing shows compensation-related awards and conversions, with no open-market purchases or sales.
ACADIA PHARMACEUTICALS INC director Laura Brege reported equity compensation and option activity. She exercised 8,107 previously granted restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 23,202 shares.
On the same date, she received a new grant of 9,311 restricted stock units, each representing a right to one share of common stock, and a grant of 16,004 director stock options with an exercise price of $21.66 per share, expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting. Brege has elected to defer receipt of the shares underlying the new restricted stock units until specified future events such as a set anniversary date, ceasing board service, or a change in control under the company’s 2024 Equity Incentive Plan.
ACADIA PHARMACEUTICALS INC director Jonathan Poole reported equity compensation activity, including option exercises and new awards. He exercised derivative securities for 2,010 shares of common stock and now holds 2,010 common shares directly. He also received 9,311 restricted stock units and 16,004 director stock options.
The 9,311 restricted stock units each represent a right to one share of common stock and will vest in full on the earlier of one year from grant or the next annual stockholder meeting, with settlement deferred based on his election. The 16,004 stock options vest quarterly over one year following the grant date and have an exercise price of $21.66 per share.
ACADIA PHARMACEUTICALS director Elizabeth A. Garofalo reported equity compensation activity centered on RSUs and stock options. On May 29, 2026, she exercised 8,107 restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 33,489 shares.
She also received a new grant of 9,311 restricted stock units, each representing one future share of common stock, and 16,004 director stock options with a strike price of $21.66 per share that vest quarterly over one year. The new RSUs will vest in full on the earlier of one year from grant or the next annual meeting, and she has elected to defer receipt of the underlying shares until specified future triggers.
ACADIA PHARMACEUTICALS director James M. Daly reported equity compensation activity on May 29, 2026. He exercised previously granted restricted stock units, receiving 8,107 shares of common stock, and held 12,148 common shares directly after these transactions.
On the same date, he was granted 9,311 restricted stock units, each representing one share of common stock, and 16,004 director stock options with an exercise price of $21.66 per share expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units are scheduled to vest in full on the earlier of one year after grant or the next annual meeting, with Daly electing to defer receipt of the underlying shares under the company’s 2024 Equity Incentive Plan.
Acadia Pharmaceuticals Inc. reported that stockholders approved an amendment to its 2024 Equity Incentive Plan, increasing the number of common shares authorized for issuance under the plan by 5,209,670. This approval occurred at the company’s 2026 Annual Meeting of Stockholders, following prior approval of the amendment by the board.
At the meeting, three Class I directors were elected, with each nominee receiving over 128 million votes in favor. Stockholders also approved the other proposals presented, with support levels generally above 147 million votes for key items, and the company has filed the amended equity plan as Exhibit 10.1.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara sold 5,401 shares of common stock in an open-market sale at a weighted average price of $21.18 per share. After the transaction, he directly owns 24,509 shares, including 781 shares acquired on May 15, 2026 through an employee stock purchase plan.
ACAD Form 144 filing lists proposed sales of Common stock tied to several benefit plans and recent dispositions by a reported holder. The excerpt shows Performance Shares: 3,857 and Employee Stock Purchase Plan allocations of 491 and 1,053. It also records four reported past dispositions by James Kihara totaling 4,304 shares on 03/25/2026, 03/26/2026, 04/07/2026, and 05/04/2026